The latest price target for Foghorn Therapeutics (NASDAQ:FHTX) was reported by HC Wainwright & Co. on December 17, 2024. The analyst firm set a price target for $13.00 expecting FHTX to rise to within 12 months (a possible 152.92% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Foghorn Therapeutics (NASDAQ:FHTX) was provided by HC Wainwright & Co., and Foghorn Therapeutics reiterated their buy rating.

There is no last upgrade for Foghorn Therapeutics

The last downgrade for Foghorn Therapeutics Inc happened on August 24, 2022 when Morgan Stanley changed their price target from $25 to $15 for Foghorn Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $20.00 to $13.00. The current price Foghorn Therapeutics (FHTX) is trading at is $5.14, which is out of the analyst’s predicted range.